General Otolaryngology
In response to Epistaxis in the setting of antithrombotic therapy: A comparison between factor Xa inhibitors, warfarin, and antiplatelet agents
First published: 06 February 2019
No abstract is available for this article.
BIBLIOGRAPHY
- 1Glikson E, Chavkin U, Madgar O, et al. Epistaxis in the setting of antithrombotic therapy: a comparison between factor Xa inhibitors, warfarin, and antiplatelet agents. Laryngoscope 2019; 129: 119–123.
- 2Mueck W, Becka M, Kubitza D, Voith B, Zuehlsdorf M. Population model of the pharmacokinetics and pharmacodynamics of rivaroxaban—an oral, direct factor Xa inhibitor—in healthy subjects. Int J Clin Pharmacol Ther 2007; 45: 335–344.
- 3Weitz JI, Eikelboom JW, Samama MM; American College of Chest Physicians. New antithrombotic drugs: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest 2012; 141(suppl 2): e120S–e151S.
- 4Raghavan N, Frost CE, Yu Z, et al. Apixaban metabolism and pharmacokinetics after oral administration to humans. Drug Metab Dispos 2009; 37: 74–81.
- 5Greenspon AJ. A review of oral anticoagulants in patients with atrial fibrillation. Postgrad Med 2012; 124: 7–16.
